Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well as in a Nature Medicine publication. Read more about the study results here: https://bit.ly/4snQBEr